Bluejay Diagnostics (BJDX) Asset Writedowns and Impairment (2022 - 2026)

Bluejay Diagnostics (BJDX) has 5 years of Asset Writedowns and Impairment data on file, last reported at $2880.0 in Q1 2026.

• For the quarter ending Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to $2880.0; the trailing twelve-month figure through Mar 2026 stood at $31577.0 (changed N/A YoY), and the FY2025 full-year result was $26706.0, up 682.94% from the prior year.
• Asset Writedowns and Impairment climbed to $2880.0 in Q1 2026, from -$10363.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $36574.0 in Q3 2025 to a low of -$10363.0 in Q4 2025.
• A 5-year average of $6579.1 and a median of $354.0 in 2024 frame the typical range for Asset Writedowns and Impairment.
• Peak annual rise in Asset Writedowns and Impairment reached 10231.64% in 2025, while the deepest fall reached 516.85% in 2025.
• Tracing BJDX's Asset Writedowns and Impairment over 5 years: stood at $27192.0 in 2022, then plunged by 101.77% to -$482.0 in 2023, then jumped by 615.77% to $2486.0 in 2024, then sank by 516.85% to -$10363.0 in 2025, then jumped by 127.79% to $2880.0 in 2026.
• Business Quant data shows BJDX's Asset Writedowns and Impairment at $2880.0 in Q1 2026, -$10363.0 in Q4 2025, and $36574.0 in Q3 2025.